Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell: pleasantly surprised as the sector flipped to the upside

July 24, 2019 11:03pm

With a close and an Advance/Decline (A/D) line of 27/14 compared to the open of 9/32

Pre-open indications: 1 HIT and 3 MISS

News: Pluristem (PSTI -$0.1426 or -25.08% with 7x volume) to reverse split shares 1:10; aimed at regaining compliance with NASDAQ’s minimum bid price listing requirement. Just another investor "screw" job!

Dispersion is, until it isn’t and even then it just swings…

Many sector equities are considered havens of risk because pricing is even less predictable

Markets and indexes:

The Dow closed down -79.22 points or -0.29% to 27,269.97;
The S&P closed up +10.49 points or +0.47% at 3,019.56;
The NASDAQ was up +70.10 or +0.85% to 8,321.50;

Henry’omics:

The S&P 500 and NASDAQ reached all-time highs on Wednesday as the sector soared after Tuesday’s dive.

As the DOJ planned to go after the FANG stocks re competitive prcices - suddenly were sector stocks a safer haven?

Investors were encouraged in recent days by hopes for U.S./China trade negotiations and expectations the European Central Bank and the U.S. Fed will ease monetary policy.

Pre-open post, “I seem to always questioning sustainability of those sector equities that saw sunlight yesterday. If tech is coming under attack by the DOJ, shouldn’t biotech be a safer haven even with their risk factors?”

Wednesday’s advance/decline line scenario of 45 covered companies:

The open was negative with an A/D (A/D) line of 9/32 with 2 flat and 2 acquired;
The mid-day was negative with an A/D Line of 19/21 with 3 flats and 2 acquired;
The close was positive with an A/D Line of 27/14 and 2 flats and 2 acquired;

Pre-open indications: 1 HIT and 3 MISS

uniQure (QURE) closed down -$0.80 – miss;
Sage Therapeutics (SAGE) closed down -$5.46 – miss;
BioLife Solutions (BLFS) closed up +$0.60 - miss;
ReNeuron (RENE.L) closed flat – hit;

The percentage (%) indicators:

Wednesday’s range of the 27 upside was +0.06% (CRSP) to +9.89% (CUR +$0.45 after reverse) while the 14 downside ranged from -0.55% (ALNY) to -25.07% (PSTI);
Tuesday’s range of the 19 upside was +0.05% (VCEL) to +4.15% (XON) while the 23 downside ranged from -0.30% (HSGX) to -8.12% (KOOL);
Monday’s range of the 24 upside was +0.04% (BMRN) to +7.36% (BLFS) while the 17 downside ranged from -0.10% (HSGX) to -6.34% (ADRO);

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

Wednesday the IBB closed up +0.28% while the XBI closed up +0.90%
Tuesday the IBB closed UP +0.26% while the XBI closed down -0.68%
Monday the IBB closed UP +0.23% while the XBI closed UP +0.34%

Leading decliners were:

Sage Therapeutics (SAGE -$5.46 after Tuesday’s -$1.04 and Monday’s -$1.39);
AxoGen (AXGN (-$1.340;
IONS Pharmaceuticals (IONS -$1.00 after Tuesday’s -$4.92)
uniQure (QURE -$0.80 after Tuesday’s -$2.46, Monday’s -$1.45 and Friday’s -$2.22);
Voyager therapeutics (VYGR -$0.42)

Tuesday’s incliners:

bluebird bio (BLUE +$3.40 after Tuesday’s +$0.48, Monday’s +$1.74 and Friday’s -$3.13);
Global Blood Therapeutics (GBT +$1.55)
Regenxbio (RGNX +$1.55 after Tuesday’s -$1.53 and Monday’s +$1.46);
Ultragenyx Pharmaceuticals (RARE +$1.14 after Tuesday’s -$2.79);
Spark Therapeutics (ONCE +$0.70)

Upside volume stats: to compare

Wednesday: 9 out of the 27 upside had higher than the 3 month average volume;
Tuesday: 2 out of the 19 upside had higher than the 3 month average volume;
Monday: 4 out of the 24 upside had higher than the 3 month average volume;

Downside volume stats: NOTICE

Wednesday: 3 out of the 14 downside had higher than the 3 month average volume;
Tuesday: 8 out of the 24 downside had higher than the 3 month average volume;
Monday: 2 out of the 17 downside had higher than the 3 month average volume;

2 flat – BSTG and RENE.L with 2 acquired (AST & OSIR) and the Spark Therapeutics’ (ONCE) acquisition by Roche still being delayed

July’s sessions and the beginning of Q3:

Wednesday closed POSITIVE with 27 decliners, 14 advancers, 2 flats and 2 acquired (AST & OSIR);

Tuesday closed NEGATIVE with 23 decliners, 19 advancers, 1 flat and 2 acquired (AST & OSIR);

Monday closed POSITIVE with 17 decliners, 24advancers, 2 flat and 2 acquired (AST & OSIR);

Friday closed NEGATIVE with 38 decliners, 4 advancers, 1 flat and 2 acquired (AST & OSIR);

Thursday closed POSITIVE with 14 decliners, 27 advancers, 2 flat and 2 acquired (AST & OSIR);

Wednesday closed POSITIVE with 20 decliners, 23 advancers, 0 flat and 2 acquired (AST & OSIR);

Tuesday closed NEGATIVE with 27 decliners, 15 advancers, 1 flat and 2 acquired (AST & OSIR);

Monday closed POSITIVE with 15 decliners, 26 advancers, 2 flats and 2 acquired (AST & OSIR);

Friday closed NEGATIVE with 22 decliners, 21 advancers, 0 flats and 2 acquired (AST & OSIR);

Thursday closed NEGATIVE with 26 decliners, 14 advancers, 3 flats and 2 acquired (AST & OSIR);

Wednesday closed POSITIVE with 25 decliners, 16 advancers, 2 flat and 2 acquired (AST & OSIR);

Tuesday closed NEGATIVE with 29 decliners, 13 advancers, 1 flat and 2 acquired (AST & OSIR);

Monday closed NEGATIVE with 24 decliners, 18 advancers, 1 flat and 2 acquired (AST & OSIR);

Friday closed NEGATIVE with 23 decliners, 19 advancers, 1 flat and 2 acquired (AST & OSIR);

Thursday was a holiday;

Wednesday closed POSITIVE with 10 decliners, 31 advancers, 2 flat and 2 acquired (AST & OSIR);

Tuesday closed NEGATIVE with 30 decliners, 11 advancers, 2 flat and 2 acquired (AST & OSIR);

Monday closed NEGATIVE with 23 decliners, 19 advancers, 1 flat and 2 acquired (AST & OSIR);

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.